Haleon Us Holdings Company Profile

What is the competitive landscape for HALEON US HOLDINGS

HALEON US HOLDINGS has thirty-one approved drugs.

There are eight US patents protecting HALEON US HOLDINGS drugs.

There are one hundred and ninety-six patent family members on HALEON US HOLDINGS drugs in thirty-two countries and fifteen supplementary protection certificates in eight countries.

Summary for Haleon Us Holdings

International Patents:	196
US Patents:	8
Tradenames:	28
Ingredients:	18
NDAs:	31

Drugs and US Patents for Haleon Us Holdings

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	ADVIL LIQUI-GELS	ibuprofen	CAPSULE;ORAL	020402-001	Apr 20, 1995		OTC	Yes	Yes
Haleon Us Holdings	NICORETTE	nicotine polacrilex	TROCHE/LOZENGE;ORAL	022360-001	May 18, 2009		OTC	Yes	No	8,940,772		Y
Haleon Us Holdings	TAVIST-1	clemastine fumarate	TABLET;ORAL	020925-001	Aug 21, 1992		DISCN	Yes	No
Haleon Us Holdings	NICORETTE (MINT)	nicotine polacrilex	GUM, CHEWING;BUCCAL	018612-003	Dec 23, 1998		OTC	Yes	No
Haleon Us Holdings	FLONASE ALLERGY RELIEF	fluticasone propionate	SPRAY, METERED;NASAL	205434-001	Jul 23, 2014		OTC	Yes	No

Expired US Patents for Haleon Us Holdings

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Haleon Us Holdings	NICORETTE	nicotine polacrilex	TROCHE/LOZENGE;ORAL	022360-001	May 18, 2009	5,110,605
Haleon Us Holdings	ABREVA	docosanol	CREAM;TOPICAL	020941-001	Jul 25, 2000	5,534,554
Haleon Us Holdings	AXID AR	nizatidine	TABLET;ORAL	020555-001	May 9, 1996	4,375,547
Haleon Us Holdings	CHILDREN'S ADVIL-FLAVORED	ibuprofen	SUSPENSION;ORAL	020589-002	Nov 7, 1997	10,238,640
Haleon Us Holdings	FLONASE SENSIMIST ALLERGY RELIEF	fluticasone furoate	SPRAY, METERED;NASAL	022051-002	Aug 2, 2016	7,541,350

Paragraph IV (Patent) Challenges for HALEON US HOLDINGS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	200 mg/30 mg		2004-12-27
	Capsules	60 mg		2010-09-08
	Gum	4 mg		2013-01-22
	Capsules	200 mg/38 mg		2016-02-16
	Gum	2 mg		2013-01-22

International Patents for Haleon Us Holdings Drugs

Country	Patent Number	Estimated Expiration
Singapore	151276
Taiwan	I313598
Poland	374579
South Korea	101316637
United Kingdom	0210605

Supplementary Protection Certificates for Haleon Us Holdings Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0129748	98C0042	Belgium		PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
1781277	PA2024501	Lithuania		PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726
1519731	13C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
2506844	SPC/GB18/020	United Kingdom		PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Haleon Us Holdings